Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice

A) Primary objective:

Gathering knowledge on the use of Dymista® in Asian patients who receive Dymista® for the first time in routine clinical practice; Patient's demographic;

Anamnestic background including:

• allergic and other comorbidities
• allergic conjunctivitis
• polysensitization
• current symptoms
• previous treatments of allergic rhinitis
• usage of current asthma reliever medication
• family history of allergy

B) Secondary Objective:

• Response to therapy with Dymista® nasal spray in routine clinical practice.
• Quality of sleep (by VAS)
• Troublesomeness in daily activities (by VAS)
• Patient's assessment about the regular use of Dymista®
• Patients opinion about continuation of Dymista® treatment after end of the observational period

Inclusion Criteria:

• The first prescription of Dymista® nasal spray according to the summary of product characteristics (SPC) and patient information leaflet and independently from the patient's enrollment in the study.
• Patients with moderate to severe seasonal or perennial allergic rhinitis
• For Hong Kong and Malaysia: Adult and children of age ≥ 12 years
• For Taiwan: Adult and children of age ≥ 6 years.
• For Thailand: Adults and children of age ≥ 12 years with seasonal and/or perennial allergic rhinitis OR children of age 6-11 years with only seasonal allergic rhinitis
• Acute allergic rhinitis symptoms at the day of inclusion (i.e. VAS-Score ≥50 mm)
• Signed informed consent/assent from the patient and, if applicable, the parent(s) or legal guardian(s) in compliance with local requirements.
• Ability to understand and follow the instructions for using Dymista® nasal spray according to the patient information leaflet.
• Willingness to complete and return the Patient Card.

Exclusion Criteria:

• VAS score <50 mm on day of inclusion
• Known allergic reaction from and/or intolerance to Dymista® nasal spray or any of the ingredients.
• Pregnancy/planned pregnancy or breastfeeding during this NIS
• Patients or parent(s)/legal guardians (as applicable) not able to fulfill study requirements according to the Investigator's opinion.

Use of Dymista® in Asian patients (Taiwan, Malaysia, Hongkong and Thailand) with moderate to severe seasonal or perennial allergic rhinitis under real life conditions.